Acceleron Stock Is Skyrocketing After Surprise Drug-Trial Success
Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…
Börse:
104,384$
-2,34%
Echtzeit-Aktienkurs Acceleron Pharma
Bid:
101,356$
Ask:
107,413$
Nachrichten zur Acceleron Pharma Aktie
Thinking about buying stock in Advanced Micro Devices, Ford, FuelCell Energy, Pinterest, or Acceleron Pharma-
NEW YORK , Jan. 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD,…
Acceleron Hits All-Time High On Positive Readout For Pulmonary Arterial Hypertension Drug
Shares of small-cap biopharma Acceleron Pharma Inc (NASDAQ: XLRN) are advancing to an all-time high Tuesday following a data readout.
…
The Daily Biotech Pulse: Accelerons Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics
Heres a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week…
Accelerons Sotatercept achieved primary and secondary endpoints in PULSAR trial in pulmonary arterial hypertension
In patients on stable background PAH-specific therapies, sotatercept demonstrated a statistically significant reduction in pulmonary vascular resistance (PVR), the trials…
23 Biotechnology Stocks Moving In Mondays After-Market Session
Gainers
¢ Acceleron Pharma, Inc. (NASDAQ:XLRN) stock moved upwards by 66.3% to $87.90 during Mondays after-market session. The most recent rating…
XLRN Soars, FDA Approves Triple Combo Pill For Type 2 Diabetes, MGEN On Watch
Todays Daily Dose brings you news about Acceleron Pharmas pulmonary arterial hypertension trial data; FDA approval of Lillys combination tablet…
Acceleron Shares Surge as Its Hypertension Drug Meets Trial Endpoints
The new drug treats high blood pressure in the lungs....…
Acceleron Soars in After-Hours Trading on Positive Trial Results for Hypertension Treatment
Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…
Acceleron Pharma stock soars more than 50% on hypertension drug study
Acceleron Pharma Inc. shares surged in the extended session late Monday after the biotech drug maker said its hypertension…
Accelerons sotatercept successful in PAH study; shares up 55% after hours
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Acceleron business chief to depart
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Acceleron Pharma (XLRN) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Acceleron, Fulcrum Therapeutics Ink Deal for Pulmonary Disease
Acceleron (XLRN) signs a collaboration/license pact with Fulcrum Therapeutics aimed at identifying small molecules designed to modulate specific pathways targeting…
Acceleron signs pulmonary research and discovery deal with Fulcrum Therapeutics
As part of the collaboration and licence agreement, the companies will work together to detect small molecules designed to modulate…
Acceleron Pharma teams up with Fulcrum Therapeutics in pulmonary diseases
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Acceleron Pharma (XLRN) Presents At 2019 ASH Annual Meeting - Slideshow
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Bristol-Myers Reblozyl to be Reviewed by FDA Committee
Bristol-Myers (BMY) and Acceleron Pharma Inc.s sBLA for Reblozyl in patients with myelodysplastic syndromes will be reviewed by the FDAs…
Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS
Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administrations (FDA)…
Acceleron Heads Toward Commercial Success
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug
Celgene (CELG) and partner Acceleron obtain FDA approval for Reblozyl for the treatment of anemia in adult patients with beta…
Acceleron Pharma up 7% on FDA nod for luspatercept
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q3 2019 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Acceleron Pharma Inc (XLRN) Q3 2019 Earnings Call Transcript
XLRN earnings call for the period ending ....…
Accelerons Q3 Results Focus Squarely on Its Celgene Collaboration
The biotechs Q3 results and future fortunes hinge on approvals for the blood-disease drug it licensed to Celgene....…
Acceleron Pharma Inc. 2019 Q3 - Results - Earnings Call Presentation
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Acceleron Pharma EPS misses by $0.04, misses on revenue
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Heres Why Acceleron Pharma Stock Fell 12% in September
The biotechs pipeline is shrinking, but investors should focus on what will drive near-term value....…
Dont Dismiss Acceleron Despite Its Recent Clinical Setback
The small pharma company had disappointing results from its second phase clinical trials. Heres why its too soon to throw…
Acceleron Discontinues Mid-Stage Muscular Dystrophy Study
Acceleron Pharmas (XLRN) pipeline candidate, ACE-083, fails to translate muscle volume growth into improvements in functional tests in FSHD patients.…
Acceleron Gives Up on Rare Genetic Disease. Analysts Are Still Bullish on the Stock.
Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…
Acceleron Pharma stock price target cut to $55 from $62 at SVB Leerink
Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…
The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study
Heres a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech stocks hitting 52-week…
XLRN Pulls The Plug On FSHD Study, KPTI Well Funded, ACRS Up On Wart Trial Data
Todays Daily Dose brings you news about Acceleron Pharma pulling the plug on facioscapulohumeral muscular dystrophy trial; Aclaris Therapeutics THWART-2…
Acceleron Pharma stock down 4% after company halts treatment trial
Shares of Acceleron Pharma Inc. fell nearly 4% in the extended session Monday after the biopharmaceutical company said one…
Acceleron bails on candidate ACE-083; shares down 3% after hours
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
FDA Grants Orphan Drug Status to Accelerons PAH Candidate
The FDA assigns an orphan drug status to Accelerons (XLRN) investigational therapy sotatercept for the treatment of patients with pulmonary…
Acceleron gets FDA orphan drug designation for sotatercept in pulmonary arterial hypertension
"Were pleased that the FDA has granted this designation for sotatercept, said Janethe de Oliveira Pena, MD, PhD, Vice President,…
Accelerons Pulmonary Arterial Hypertension Asset Receives Orphan Drug Designation
Cambridge, Massachusetts-based Acceleron Pharma Inc (NASDAQ: XLRN)read more...…
Acceleron Pharma Inc. 2019 Q2 - Results - Earnings Call Slides
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Acceleron Pharma Inc (XLRN) Q2 2019 Earnings Call Transcript
XLRN earnings call for the period ending June 30, 2019....…
What Youll Want to Know About Acceleron Pharmas Q2 Update
The big story for Acceleron: waiting on good news for luspatercept....…
ALNY To Face FDA In Feb., PODD Ups Outlook Again, Catalysts Galore For XLRN
Todays Daily Dose brings you news about Cardiovascular Systemss acquisition; upcoming catalysts of Revance Therapeutics and Acceleron Pharma; Insulets stellar…
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q2 2019 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Acceleron completes target enrollment in phase 2 trial of Sotatercept in PAH
The Company now expects to report top-line results during the first quarter of 2020. "Were thrilled with PULSARs rapid enrollment…
Celgene & Accelerons BLA for Luspatercept Accepted by FDA
Celgene (CELG) along with partner Acceleron submits application for luspatercept to the FDA....…
The Investment Thesis On Acceleron Pharma
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Acceleron Pharma Inc (XLRN) Q1 2019 Earnings Call Transcript
XLRN earnings call for the period ending March 31, 2019....…
Acceleron Pharmas (XLRN) CEO Habib Dable on Q1 2019 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Acceleron Pharma (XLRN) Reports Q1 Loss, Misses Revenue Estimates
Acceleron (XLRN) delivered earnings and revenue surprises of -10.45% and -24.76%, respectively, for the quarter ended March 2019. Do the…